Rhumbline Advisers Immuno Gen, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$12.46 - $29.95 $34,912 - $83,919	-2,802 Reduced 0.77%	361,594 $10.7 Million
Q3 2023 Nov 09, 2023	BUY	$14.09 - $19.87 $6,326 - $8,921	449 Added 0.12%	364,396 $5.78 Million
Q2 2023 Aug 08, 2023	BUY	$3.75 - $20.05 $162,918 - $871,072	43,445 Added 13.56%	363,947 $6.87 Million
Q1 2023 May 11, 2023	SELL	$3.67 - $4.92 $7,508 - $10,066	-2,046 Reduced 0.63%	320,502 $1.23 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $14,651 - $20,318	3,220 Added 1.01%	322,548 $1.6 Million
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $92,538 - $133,644	20,656 Added 6.92%	319,328 $1.53 Million
Q2 2022 Aug 11, 2022	BUY	$3.15 - $5.76 $146,739 - $268,323	46,584 Added 18.48%	298,672 $1.34 Million
Q1 2022 May 12, 2022	SELL	$4.26 - $7.48 $69,148 - $121,415	-16,232 Reduced 6.05%	252,088 $1.2 Million
Q4 2021 Feb 10, 2022	SELL	$4.75 - $7.5 $15,608 - $24,645	-3,286 Reduced 1.21%	268,320 $1.99 Million
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $23,026 - $30,228	4,587 Added 1.72%	271,606 $1.54 Million
Q2 2021 Aug 05, 2021	SELL	$5.79 - $8.6 $90,746 - $134,787	-15,673 Reduced 5.54%	267,019 $1.76 Million
Q1 2021 May 06, 2021	SELL	$6.5 - $10.53 $58,714 - $95,117	-9,033 Reduced 3.1%	282,692 $2.29 Million
Q4 2020 Feb 10, 2021	BUY	$3.7 - $7.66 $121,352 - $251,232	32,798 Added 12.67%	291,725 $1.88 Million
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $106,170 - $150,484	-30,774 Reduced 10.62%	258,927 $932,000
Q2 2020 Aug 13, 2020	BUY	$3.32 - $5.34 $200,474 - $322,450	60,384 Added 26.33%	289,701 $1.33 Million
Q1 2020 May 06, 2020	BUY	$2.12 - $6.8 $43,146 - $138,393	20,352 Added 9.74%	229,317 $782,000
Q4 2019 Feb 05, 2020	BUY	$2.25 - $5.8 $5,719 - $14,743	2,542 Added 1.23%	208,965 $1.07 Million
Q3 2019 Oct 23, 2019	BUY	$2.22 - $3.39 $17,602 - $26,879	7,929 Added 3.99%	206,423 $500,000
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $26,677 - $48,909	14,821 Added 8.07%	198,494 $431,000
Q1 2019 May 01, 2019	SELL	$2.41 - $5.91 $12,423 - $30,466	-5,155 Reduced 2.73%	183,673 $498,000
Q4 2018 Jan 31, 2019	BUY	$3.94 - $9.7 $247,408 - $609,101	62,794 Added 49.82%	188,828 $906,000
Q3 2018 Nov 07, 2018	BUY	$8.6 - $11.26 $6,888 - $9,019	801 Added 0.64%	126,034 $1.19 Million
Q2 2018 Aug 06, 2018	BUY	$9.52 - $12.15 $288,465 - $368,157	30,301 Added 31.92%	125,233 $1.22 Million
Q1 2018 May 02, 2018	BUY	$6.7 - $12.95 $27,356 - $52,874	4,083 Added 4.49%	94,932 $999,000
Q4 2017 Feb 09, 2018	SELL	$5.07 - $7.92 $45,310 - $70,781	-8,937 Reduced 8.96%	90,849 $582,000
Q3 2017 Nov 06, 2017	BUY	$5.4 - $8.47 $538,844 - $845,187	99,786	99,786 $763,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account